Ongoing Clinical Trials for Pelizaeus-Merzbacher Disease
There are currently 2 ongoing clinical trials exploring new treatments for Pelizaeus-Merzbacher Disease, a rare genetic disorder affecting the nervous system. These studies are testing different approaches to help manage symptoms and improve motor function in affected children.
Clinical trial locations
- France
- Germany
- Netherlands
Study on the Safety and Effects of ION356 for Patients with Pelizaeus-Merzbacher Disease
This clinical trial is investigating a new treatment approach for Pelizaeus-Merzbacher Disease using a medication called ION356. This medicine is a special type of drug known as an antisense oligonucleotide, which works at the genetic level to address the underlying cause of the disease.
Who can join: This study is looking for male participants between 2 and 17 years old who have a confirmed diagnosis of Pelizaeus-Merzbacher Disease. The diagnosis must be genetically confirmed through a certified laboratory test showing a duplication of the PLP1 gene. Participants must also have symptoms and brain scans that match the diagnosis, and they need to be able to travel to the study center and follow all study requirements.
Who cannot join: This trial is only open to males within the specified age range who meet the diagnostic criteria. Females and individuals outside the 2-17 age range cannot participate.
What the study involves: ION356 is given as an injection directly into the space around the spinal cord, a method called intrathecal administration. The main goal is to evaluate how safe the medication is and how well patients tolerate it. Researchers will also study how the body processes the medicine by monitoring its concentration in the blood and spinal fluid over time. Throughout the study, participants will have regular health check-ups, including blood tests, neurological examinations, and other assessments to ensure their safety. The study is expected to continue until September 2029, allowing researchers to gather important long-term information.
Investigational drug: ION356 is designed to work at the genetic level to target the PLP1 gene duplication that causes Pelizaeus-Merzbacher Disease. It is currently in Phase 1b clinical trials.
Studying the Effects of Deferiprone on Motor Function in Children with Pelizaeus-Merzbacher Disease
This clinical trial is exploring whether a medication called deferiprone can help improve movement and coordination in children with Pelizaeus-Merzbacher Disease. Deferiprone is taken as an oral solution, meaning it is a liquid that is swallowed.
Who can join: This study is looking for male children aged 8 years or younger with a genetically confirmed diagnosis of Pelizaeus-Merzbacher Disease. The diagnosis must show a specific type of genetic change in the PLP1 gene, either a missense mutation or a triplication of the gene. Participants must also have a brain MRI that supports the diagnosis, and they need to live within a reasonable travel distance from Amsterdam. The child must have either the connatal or classic form of the disease, meaning they cannot sit without support or have a genetic mutation that predicts this severe form. Weekly blood samples must be possible to take at or near the participant’s home.
Who cannot join: Girls cannot participate in this trial, only boys are eligible. Children who do not have Pelizaeus-Merzbacher Disease or who fall outside the specified age range also cannot join.
What the study involves: The primary focus of this trial is to evaluate whether deferiprone can improve motor function, particularly the ability to move, sit, and coordinate movements. Participants will take the medication as an oral solution, and some may receive a placebo instead. The study will use a tool called the gross motor function measurement (GMFM-88) to assess changes in movement abilities. Additional assessments will include brain imaging techniques such as MRI and DTI scans, as well as evaluations of general health, quality of life, hand function, communication, swallowing abilities, and adaptive behavior. The trial is expected to conclude in May 2027.
Investigational drug: Deferiprone works as an iron chelating agent, which means it binds to excess iron in the body and helps remove it. This process may reduce oxidative stress and potentially improve neurological function in children with this condition.
Summary
These two clinical trials represent important research efforts to find new treatments for Pelizaeus-Merzbacher Disease, a rare genetic disorder affecting the nervous system. The trials are taking different approaches: one focuses on a genetic-level treatment given through spinal injection, while the other tests an oral medication that may help with iron management in the body.
Both trials are being conducted in European countries, with the Netherlands hosting both studies, and Germany and France participating in the ION356 trial. Both studies are specifically designed for male children, which reflects the X-linked pattern of inheritance of this condition. The age ranges differ between the trials, with the ION356 study accepting participants up to 17 years old, while the deferiprone study focuses on younger children aged 8 and under.
These trials offer hope for families affected by Pelizaeus-Merzbacher Disease, as they explore new ways to manage symptoms and potentially improve quality of life for children living with this challenging condition.
